PCM
MIST icon

Pentwater Capital Management’s Milestone Pharmaceuticals MIST Stock Holding History

Pentwater Capital Management’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-32,000
Closed -$512K – 150
2019
Q4 		$512K Buy
32,000
+7,000
+28% +$124K 0.01% 125
2019
Q3 		$466K Hold
25,000
– – 0.01% 135
2019
Q2 		$679K Buy
+25,000
New +$516K 0.01% 149

Other funds holding MIST

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pentwater Capital Management's MIST Position: Q1 2020 in Review

Pentwater Capital Management sold out of Milestone Pharmaceuticals (MIST) in Q1 2020, closing a stake of 32,000 shares — an estimated $512K sold.

Pentwater Capital Management first reported a position in MIST in Q2 2019 and held it in 3 quarters. The position peaked at $679K in Q2 2019. 19 funds tracked by Wall St. Rank hold MIST as of Q1 2020.

  • Pentwater Capital Management reported no remaining Milestone Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Pentwater Capital Management sold 32,000 Milestone Pharmaceuticals shares in Q1 2020, an estimated $512K.
  • Pentwater Capital Management first reported a position in Milestone Pharmaceuticals in Q2 2019 and held it in 3 quarters.
  • Pentwater Capital Management's Milestone Pharmaceuticals position peaked at $679K in Q2 2019.
  • 19 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q1 2020.

Based on Pentwater Capital Management's 13F filing for Q1 2020, filed 15 May 2020.